Company Overview
Mariposa Health is a pharmaceutical development company specializing in;
- Lung conditions
- Inflammatory conditions
It has two products that have completed initial Phase 2 clinical trials in the field of chronic obstructive pulmonary disorder (COPD) and asthma. One of our products is ready to commence Phase 2 clinical trials for the treatment of Allergic Rhinitis.
- TA-270, for the treatment of COPD
- HI-164, respiratory vaccine
After developing initial IP on the use of a vaccine to Golden staph to reduce respiratory sleep conditions, Mariposa Health then grew through acquisition;
- 2010 - Acquisition of TA-270 from Activus Pharma (Japan)
- 2014 - Acquisition of Hunter Immunology from Bioxyne Limited (Australia)
Mariposa Health has completed a deal with Shanxi Kangbao Biological Product Co., of the PR China, for the exclusive rights to develop and commercialize HI-164 in the PR China and its territories.
Mariposa Health is now well positioned for its next phase or consolidation and growth.